As per our research analysis, the Middle East and African Diabetes Devices Market has been estimated at USD 1.54 billion in 2023 and is projected to reach USD 2.09 billion by 2028, at a CAGR of 6.34% during the forecast period. Diabetes is a group of metabolic disorders, a chronic condition which is associated with an abnormally high level of sugar (glucose) in the blood. The Middle East and North Africa currently witness 35.4 million people affected with Diabetes, which is going to reach 72.1 million by 2040. The rest of the Africa region witnesses 14.2 million people affected with diabetes, and this number is said to reach 34.2 million by 2040.
The Middle East and Africa region have accounted for a prominent increase in the prevalence of diabetes in recent periods. The rate of diabetes is high in the region, which is being triggered by abnormal lifestyle patterns with an unbalanced diet. According to various research, around 74 million adults will be diagnosed with diabetes in the Middle East and Africa region in 2021, and the number is expected to reach 95 million by 2030. Around 48 million adults in the MEA region are living with impaired glucose tolerance, which puts them at risk of developing type 2 diabetes. All these factors are expected to drive market revenue growth during the forecast period. The growing technological advancements in healthcare are influencing the market players to invest in research and development activities to launch effective insulin delivery devices. These R&D activities are fueling the market growth. The government in the Middle East has recognized the threat of diabetes and brought awareness among the people by implementing education programs and launching policies and projects to help diabetic patients in the region. This kind of government initiative is boosting the market growth of diabetes devices in the region. The rising prevalence of lifestyle-related health issues such as obesity and hypertension are inducing type-2 diabetes in people, which is propelling the Middle East and Africa diabetes devices market growth.
The growing R&D activities to develop efficient and effective devices for diabetes are estimated to provide market growth opportunities. The increasing awareness among the people regarding diabetic care as they are more concerned about diabetes and its implications is expected to fuel the market growth opportunities. The increasing government initiatives and investments to educate people regarding diabetes are augmenting market value growth
There needs to be a higher medical literacy rate and awareness among the region's people. Most of the Middle East and Africa population belongs to rural areas where illiteracy rates are high, which is hampering market growth due to low awareness regarding the quality of medical facilities. Many people must be aware of the devices and the disease impacting the region's market expansion. Another factor restraining the region's market growth is the high cost of medical devices. Many African countries are economically backward where the investment in the devices is complex for the people, hindering market growth.
Some people prefer to get laboratory tests to evaluate their blood glucose level rather than use diabetic devices, which is expected to limit market expansion. People prefer laboratory tests due to their accuracy, even though they are time-consuming. The stringent regulations by the regulatory authorities for approval of product launches are challenging due to the time-consuming and complex process. The reach of medical devices is challenging in most African countries as it is economically unstable.
The Pandemic positively impacted the Middle East and Africa diabetes devices market. Diabetic patients have a high chance of infecting with COVID-19, where they experience an elevation in blood glucose, abnormal glucose variability, and diabetic complications. The prevalence of diabetes in people with COVID-19 caused severe mortality. To avoid a critical situation, the blood glucose level should be monitored regularly, increasing the adoption of self-monitoring blood glucose devices. The Pandemic has created awareness regarding remote care patients.
This research report segmented and sub-segmented into the following categories:
The Continuous glucose monitoring devices segment dominated the market with the largest share and is expected to grow significantly during the forecast period. These devices can be worn on the body and held by an adhesive patch. The sensor part of the device inserts the cannula into the top layer of the skin and collects samples to check the blood glucose level. The sensors are connected to a transmitter, which sends data to the receiving device. These reasons are boosting the market growth in this segment.
The insulin delivery system segment is projected to grow steadily during the forecast period. Insulin is highly preferred for people with extreme diabetic levels, and the growing prevalence of diabetes across the region is estimated to drive the market in this segment over the forecast period.
South Africa dominated the Middle East and Africa diabetes devices market due to increasing genetic factors for type 2 diabetes and growing awareness among the people due to government initiatives driving the market. According to the IDF Diabetes Atlas, one in nine people in South Africa has diabetes. Saudi Arabia and Iran together accounted for half of the market in the region. The rising cases of diabetes are inducing market growth opportunities through the adoption of diabetes devices for monitoring blood glucose levels. The GCC countries market is expanding and is estimated to grow steadily during the forecast period. According to the International Diabetes Federation, through the past ten years, the percentage of persons with diabetes has been stable at 18.6% in Saudi Arabia, 16.5% in UAE, and 19.3% in Qatar. The growing R&D activities and the presence of a few key market players in the countries are propelling the market growth.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]